X4 PHARMACEUTICALS, INC Payments of Stock Issuance Costs
X4 PHARMACEUTICALS, INC (XFOR) reported Payments of Stock Issuance Costs of $43.00 thousand for the 9-month period ending 2018-09-30, per its 10-Q filed 2018-11-09.
Discontinued › Cash Flow › Financing Activities
us-gaap:PaymentsOfStockIssuanceCosts · last filed 2018-11-09
- X4 PHARMACEUTICALS, INC payments of stock issuance costs for the quarter ending 2018-09-30 was $0.00.
- X4 PHARMACEUTICALS, INC payments of stock issuance costs for the quarter ending 2018-06-30 was $0.00.
- X4 PHARMACEUTICALS, INC payments of stock issuance costs for the quarter ending 2018-03-31 was $43.00K.
| Period end | Payments of Stock Issuance Costs 3 month | Payments of Stock Issuance Costs 6 month | Payments of Stock Issuance Costs 9 month |
|---|---|---|---|
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $0.00 derived: sum of 2 quarters · filed 2018-11-09 | $43.00K 10-Q · filed 2018-11-09 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-13 | $43.00K 10-Q · filed 2018-08-13 | |
| 2018-03-31 | $43.00K 10-Q · filed 2018-05-10 | ||
| 2017-09-30 | $795.00K 10-Q · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |